| Title |
Cost considerations in the management of atrial fibrillation – impact of dronedarone
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, March 2012
|
| DOI | 10.2147/ceor.s16675 |
| Pubmed ID | |
| Authors |
Yaariv Khaykin, Yana Shamiss |
| Abstract |
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance. This review will discuss AF treatment strategies and economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 26 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 19% |
| Student > Master | 4 | 15% |
| Student > Doctoral Student | 3 | 11% |
| Student > Ph. D. Student | 3 | 11% |
| Researcher | 3 | 11% |
| Other | 3 | 11% |
| Unknown | 6 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 41% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Economics, Econometrics and Finance | 2 | 7% |
| Social Sciences | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 7 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2012.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#429
of 514 outputs
Outputs of similar age
#132,340
of 168,428 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#3
of 3 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 514 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,428 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.